Human Longevity makes three oncology appointments
pharmafile | February 4, 2016 | Appointment | Research and Development |Â Â human longevityÂ
Human Longevity, the genomics-based, technology company, has appointed ‘several key people’ for its oncology genomics program.
Dr Kenneth Bloom will join the company as the new head of oncology and immunotherapy; Dr Stephen Schoenberger will lead cancer vaccine efforts and Dr Ezra Cohen, who is also associate director and professor of medicine at Moores Cancer Center in San Diego, will be a staff oncologist.
Dr Bloom has more than 30 years of clinical and business experience and has been an early adopter and big proponent of information technology to revolutionise pathology and other areas of medicine. He is also a prolific and renowned researcher and lecturer in pathology, cancer, telemedicine, and informatics.
Dr Cohen is also an internationally recognised expert on novel cancer therapies and co-leads the Solid Tumor Therapeutics program at Moores Cancer Center. Much of his clinical work has focused on squamous cell carcinomas and cancers of the thyroid, salivary gland, and HPV-related oropharyngeal cancers. He has also been consulting with HLI for approximately a year, as the company has been developing its oncology program, and will continue this work in his new part time role.
Schoenberger is currently professor in cellular immunology at the La Jolla Institute for Allergy and Immunology, and an adjunct professor of medicine at University of California San Diego, Moores Cancer Center. He has authored nearly 100 scientific papers, along with numerous reviews and book chapters.
Craig Venter, the Human Genom Project pioneer and co-founder and chief executive of HLI says: “We are excited to have Ken, Stephen and Ezra on the HLI team and are confident their combined clinical and scientific expertise will greatly enhance our oncology program. We have been working over the last year on developing our oncology program with help from Ezra. We will look to Ken and his team to further develop and commercialize this important area of our business.”
Related Content
AstraZeneca to sequence genomes to develop new drugs
AstraZeneca (LSE: AZN) has announced an integrated genomics initiative that aims to transform the drug …
Genentech and Human Longevity ink genomics deal
Genentech is partnering with US genetics firm Human Longevity (HLI) in another 2015 genomics deal …
